Arcturus Therapeutics names Moncef Slaoui as Chair Designate
Holdings Inc. (NASDAQ: ARCT), a company specializing in mRNA medicines for infectious diseases and rare disorders, has appointed Dr. Moncef Slaoui as its Chair Designate. Dr. Slaoui, a notable figure ...
Arcturus Therapeutics appoints Moncef Slaoui as chair designate
Arcturus Therapeutics (ARCT) announced the appointment of Moncef Slaoui as chair designate. Slaoui has been serving on the company’s board of ...
Arcturus Therapeutics Announces Appointment of Moncef Slaoui, Ph.D., as Chair Designate
Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company ...
Arcturus Therapeutics' SWOT analysis: mRNA innovator's stock faces pivotal year
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT), a commercial-stage biotechnology company with a market capitalization of $428 million specializing in mRNA therapeutics and vaccines, stands at a ...
Ed Arce’s Buy Rating on Arcturus Therapeutics Driven by Strategic Advancements and Strong Market Positioning
In a report released today, Ed Arce from H.C. Wainwright maintained a Buy rating on Arcturus Therapeutics (ARCT – Research Report), with a ...
Arcturus Therapeutics to Present at Guggenheim Securities SMID Cap Biotech Conference
Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company ...
Arcturus Therapeutics (NASDAQ:ARCT) Now Covered by Analysts at BTIG Research
BTIG Research began coverage on shares of Arcturus Therapeutics (NASDAQ:ARCT – Get Free Report) in a research report issued on Tuesday, MarketBeat reports. The brokerage set a “buy” rating and a ...
Arcturus: Downgrading As mRNA Promise Meets Market Reality
Arcturus Therapeutics Holdings Inc. stock is down 46% since Sept. 2023 coverage; mRNA sector faces headwinds with public ...